Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective (Q26864207)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective	scientific article

Statements

scholarly article

1 reference

Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective (English)

1 reference

0 references

1 reference

based on heuristic

inferred from title

postmenopausal osteoporosis

1 reference

based on heuristic

inferred from title

author name string

Steven Boonen

1

1 reference

Serge Ferrari

2

1 reference

Paul D Miller

3

1 reference

Erik F Eriksen

4

1 reference

Philip N Sambrook

5

1 reference

Juliet Compston

6

1 reference

Ian R Reid

7

1 reference

Dirk Vanderschueren

8

1 reference

Felicia Cosman

9

1 reference

language of work or name

1 reference

publication date

May 2012

1 reference

Journal of Bone and Mineral Research

1 reference

27

1 reference

5

1 reference

963-74

1 reference

How can bone turnover modify bone strength independent of bone mass?

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Markers of bone turnover for the prediction of fracture risk

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Bone turnover markers: understanding their value in clinical trials and clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Biomarkers of bone health and osteoporosis risk

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Risedronate reduces intracortical porosity in women with osteoporosis.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Bone response to termination of oestrogen treatment

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Fracture risk remains reduced one year after discontinuation of risedronate

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Adverse effects of bisphosphonates

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Renal safety of intravenous bisphosphonates in the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Osteoporosis medication and reduced mortality risk in elderly women and men.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Denosumab and bisphosphonates: different mechanisms of action and effects.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Long-term use of bisphosphonates in osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1570

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26864207&oldid=1978533806"